Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14329380 | 0.85 | L3MBTL3 (0.47) | SMN1; SMN2MGLLCACNA1HMEN1KMT2A | |
| SCHEMBL9980080 | 0.85 | L3MBTL3 (0.47) | SMN1; SMN2MGLLCACNA1HMEN1KMT2A | |
| SCHEMBL9980051 | 0.85 | L3MBTL3 (0.47) | SMN1; SMN2MGLLCACNA1HMEN1KMT2A | |
| SCHEMBL9980054 | 0.83 | CXCR2 (0.56) | CACNA1HCXCR2 | |
| SCHEMBL9980078 | 0.83 | CXCR2 (0.56) | CACNA1HCXCR2 | |
| SCHEMBL9979996 | 0.83 | CACNA1H (0.49) | MGLLCACNA1HKDM4EALDH1A1CXCR2 | |
| SCHEMBL30515712 | 0.83 | CACNA1H (0.49) | MGLLCACNA1HKDM4EALDH1A1CXCR2 | |
| SCHEMBL20817497 | 0.74 | CXCR2 (0.48) | MGLLCACNA1HCXCR2 | |
| SCHEMBL9979958 | 0.74 | L3MBTL3 (0.47) | CYP2D6MGLLCACNA1HMEN1KMT2A | |
| SCHEMBL9980040 | 0.74 | L3MBTL3 (0.47) | CYP2D6MGLLCACNA1HMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651891-B1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-8648118-B2 | Bicyclic ring system substituted amide functionalised phenols as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648118-B2 | Bicyclic ring system substituted amide functionalised phenols as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012080456-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | CXCR2, CCR2, CCR1 | CYP1A2 298/4885CYP2D6 373/4885SMN1; SMN2 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.